3PBIOVIAN News and Resources

3PBIOVIAN, a CDMO partner in biopharmaceutical manufacturing, has announced the launch of its AAVion Platform—an end-to-end adeno-associated virus (AAV) manufacturing solution aimed at accelerating gene therapy development. The platform is now available to biotech and pharmaceutical companies globally. The AAVion

3PBIOVIAN, a contract development and manufacturing organisation (CDMO), has completed its first year following the merger of BIOVIAN and 3P Biopharmaceuticals. With facilities in Noaín, Spain, and Turku, Finland, the company provides process development and manufacturing solutions for recombinant proteins,

3PBIOVIAN and Eleva have formed a strategic alliance to advance the manufacturing of clinical-grade biologics, including Eleva’s Factor H (CPV-104) program. Under the agreement, 3PBIOVIAN, a contract development and manufacturing organisation (CDMO), will provide production capacity to support Eleva’s clinical

3PBIOVIAN, a pan-European biologics CDMO, has recently partnered with Rokote Laboratories, a vaccine development company, to produce GMP batches of their adenovirus vector-based COVID-19 vaccine, FINCoVac 2.1. This vaccine is designed to induce a strong mucosal immune response in the nasopharyngeal